Carbapenem-Resistant Enterobacteriaceae Infection Clinical Trial
Official title:
A Retrospective Single Center Study of the Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in PICU Hospitalized Children
Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly identified in children in China. Pediatric intensive care unit (PICU) is the high-risk area. However, data on the epidemiology of CRE in hospitalized children in PICU are limited. The objectives of this study are to characterize the risk factors for colonization or infection with CRE and describe the microbiologic characteristics of pediatric CRE isolates. The investigators will perform a single retrospective study from January 2018 to December 2019 at PICU of Children's Hospital of Fudan University .
The investigators intend to enroll all children who were hospitalized in pediatric intensive care unit PICU of Children's Hospital of Fudan University from January 2018 to December 2019. Children who had positive cultures for any Enterobacteriaceae species before their admission will be excluded. Children with a PICU length of day less than 48h will also be excluded. According to their clinical cultures results, they will be divided into non-CREćCRE colonization and CRE infection. CRE was defined according to the 2015 Centers for Disease Control and Prevention (CDC) definition as an isolate resistant to imipenem, meropenem, or ertapenem. Clinical and demographic data will be collected from the electronic health record. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06051513 -
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
|
N/A | |
| Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
| Completed |
NCT04146337 -
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
|
Phase 2/Phase 3 | |
| Completed |
NCT04167228 -
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
|
||
| Terminated |
NCT04876430 -
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
|
Phase 2/Phase 3 | |
| Enrolling by invitation |
NCT03924934 -
Community-associated Highly-Resistant Enterobacterales
|
||
| Recruiting |
NCT04583098 -
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
|
||
| Withdrawn |
NCT04785924 -
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
|
Phase 4 | |
| Terminated |
NCT05258851 -
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
|
Phase 3 | |
| Not yet recruiting |
NCT04746222 -
Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04014413 -
Safety and Efficacy of Fecal Microbiota Transplantation
|
N/A | |
| Recruiting |
NCT05871476 -
Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
|
N/A | |
| Recruiting |
NCT05850871 -
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
|
N/A | |
| Terminated |
NCT05210387 -
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
|
N/A | |
| Not yet recruiting |
NCT06210542 -
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
|
||
| Not yet recruiting |
NCT05981430 -
Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae
|
N/A | |
| Recruiting |
NCT06258551 -
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
|
||
| Recruiting |
NCT05979545 -
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
|
Phase 4 | |
| Completed |
NCT04790565 -
Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae
|
Phase 2/Phase 3 |